Global Market Direct’s pharmaceuticals report, “Sylentis - Product Pipeline Review - 2013” provides data on the Sylentis’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sylentis’s corporate website, SEC filings, investor presentations and featured press releases, both from Sylentis and industry-specific third party sources, put together by Global Markets Direct’s team.
- Sylentis - Brief Sylentis overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Sylentis human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Sylentis with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Sylentis’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Sylentis’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Sylentis in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Sylentis’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Sylentis. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Sylentis and identify potential opportunities in those areas.
Table Of Contents
Sylentis - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Sylentis Snapshot 5 Sylentis Overview 5 Key Information 5 Key Facts 5 Sylentis - Research and Development Overview 6 Key Therapeutic Areas 6 Sylentis - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Sylentis - Pipeline Products Glance 10 Sylentis Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Sylentis - Early Stage Pipeline Products 11 Pre-Clinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Sylentis - Drug Profiles 13 Drug For Arthritis 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Drug For Cerebral Ischemia 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 Drug For Crohn's Disease And Ulcerative Colitis 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 Drug For Dementia 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 SYL-040012 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 SYL-1001 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 Sylentis - Pipeline Products by Route of Administration 20 Sylentis - Pipeline Products By Mechanism of Action 21 Sylentis - Recent Pipeline Updates 22 Sylentis - Locations And Subsidiaries 23 Head Office 23 Sylentis, Recent Developments 24 Sylentis- Press Release 24 Feb 27, 2013: Sylentis Commences Phase II Clinical Trials With SY1001 For Treating Eye Discomfort Associated With Dry Eye Syndrome 24 Sep 06, 2010: Sylentis Receives Authorization To Commence Phase I/II Clinical Trial With SYL040012 For Treating Elevated Intraocular Pressure And Glaucoma 24 Jul 06, 2010: Sylentis Completes Phase I trial With SYL040012 To Treat Elevated Intraocular Pressure And Glaucoma 25 Financial Deals Landscape 26 Sylentis, Deals Summary 26 Sylentis, Pharmaceuticals and Healthcare, Deal Details 27 Licensing Agreements 27 Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables
Sylentis, Key Information 5 Sylentis, Key Facts 5 Sylentis - Pipeline by Indication, 2013 7 Sylentis - Pipeline by Stage of Development, 2013 8 Sylentis - Monotherapy Products in Pipeline, 2013 9 Sylentis - Phase II, 2013 10 Sylentis - Pre-Clinical, 2013 11 Sylentis - Discovery, 2013 12 Sylentis - Pipeline By Route of Administration, 2013 20 Sylentis - Pipeline Products By Mechanism of Action, 2013 21 Sylentis - Recent Pipeline Updates, 2013 22 Sylentis, Deals Summary 26 Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 27
List of Figures
Sylentis - Pipeline by Indication, 2013 7 Sylentis - Pipeline by Stage of Development, 2013 8 Sylentis - Monotherapy Products in Pipeline, 2013 9 Sylentis - Pipeline By Route of Administration, 2013 20 Sylentis - Pipeline Products By Mechanism of Action, 2013 21